| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J B Stroud, T P Freeman, R Leech, C Hindocha, W Lawn, D J Nutt, H V Curran, R L Carhart-Harri. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology. vol 235. issue 2. 2018-12-31. PMID:29085980. |
psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. |
2018-12-31 |
2023-08-13 |
Not clear |
| R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling, J A Rickard, B Forbes, A Feilding, D Taylor, H V Curran, D J Nut. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. vol 235. issue 2. 2018-12-31. PMID:29119217. |
psilocybin with psychological support for treatment-resistant depression: six-month follow-up. |
2018-12-31 |
2023-08-13 |
Not clear |
| Andy Whelan, Mark I Johnso. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain management. vol 8. issue 3. 2018-10-24. PMID:29722608. |
tentative evidence from a systematic review suggests that lsd (7 studies, 323 participants) and psilocybin (3 studies, 92 participants) may be beneficial for depression and anxiety associated with distress in life-threatening diseases. |
2018-10-24 |
2023-08-13 |
human |
| Michael P Bogenschutz, Stephen Ros. Therapeutic Applications of Classic Hallucinogens. Current topics in behavioral neurosciences. vol 36. 2018-09-20. PMID:28512684. |
to provide a clinical perspective, case summaries are provided of two individuals who received treatment in recent controlled trials of psilocybin: one being treated for alcoholism, the other suffering from anxiety and depression related to fear of death due to a cancer diagnosis. |
2018-09-20 |
2023-08-13 |
human |
| Rafael G Dos Santos, José Carlos Bouso, Miguel Ángel Alcázar-Córcoles, Jaime E C Halla. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert review of clinical pharmacology. vol 11. issue 9. 2018-09-17. PMID:30102078. |
expert commentary: psilocybin and lsd reduced anxiety and depression in cancer patients and symptoms of alcohol and tobacco dependence, and ayahuasca reduced depression symptoms in treatment-resistant depression. |
2018-09-17 |
2023-08-13 |
Not clear |
| Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak, Philip Ashton, Lily Fitzgerald, Jack Stroud, David J Nutt, Robin L Carhart-Harri. Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. Journal of affective disorders. vol 230. 2018-09-04. PMID:29407543. |
natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. |
2018-09-04 |
2023-08-13 |
Not clear |
| John D McCorvy, Reid Hj Olsen, Bryan L Rot. Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2018-08-24. PMID:27909171. |
psilocybin for depression and anxiety associated with life-threatening illnesses. |
2018-08-24 |
2023-08-13 |
Not clear |
| Randall T Brown, Christopher R Nicholas, Nicholas V Cozzi, Michele C Gassman, Karen M Cooper, Daniel Muller, Chantelle D Thomas, Scott J Hetzel, Kelsey M Henriquez, Alexandra S Ribaudo, Paul R Hutso. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clinical pharmacokinetics. vol 56. issue 12. 2018-06-28. PMID:28353056. |
psilocybin is a psychedelic tryptamine that has shown promise in recent clinical trials for the treatment of depression and substance use disorders. |
2018-06-28 |
2023-08-13 |
Not clear |
| Robin L Carhart-Harris, Guy M Goodwi. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443617. |
in this circumspective piece, rlc-h and gmg share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression. |
2018-05-16 |
2023-08-13 |
human |
| David Nut. Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2018-01-31. PMID:27909163. |
psilocybin for anxiety and depression in cancer care? |
2018-01-31 |
2023-08-13 |
Not clear |
| Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L Schmid. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909164. |
rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. |
2017-12-27 |
2023-08-13 |
Not clear |
| Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L Schmid. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909164. |
historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. |
2017-12-27 |
2023-08-13 |
Not clear |
| Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedins. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909165. |
psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. |
2017-12-27 |
2023-08-13 |
human |
| Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedins. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909165. |
previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. |
2017-12-27 |
2023-08-13 |
human |
| Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedins. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909165. |
the effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. |
2017-12-27 |
2023-08-13 |
human |
| Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H Curran, David J Nut. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The lancet. Psychiatry. vol 3. issue 7. 2017-11-08. PMID:27210031. |
psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. |
2017-11-08 |
2023-08-13 |
Not clear |
| Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H Curran, David J Nut. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The lancet. Psychiatry. vol 3. issue 7. 2017-11-08. PMID:27210031. |
here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression. |
2017-11-08 |
2023-08-13 |
Not clear |
| Suravi Patr. Return of the psychedelics: Psilocybin for treatment resistant depression. Asian journal of psychiatry. vol 24. 2017-02-14. PMID:27931907. |
return of the psychedelics: psilocybin for treatment resistant depression. |
2017-02-14 |
2023-08-13 |
Not clear |
| Suravi Patr. Return of the psychedelics: Psilocybin for treatment resistant depression. Asian journal of psychiatry. vol 24. 2017-02-14. PMID:27931907. |
psilocybin, the clinically most researched classic psychedelic has recently been tested for its safety and efficacy in a clinical population of treatment resistant depression. |
2017-02-14 |
2023-08-13 |
Not clear |
| Suravi Patr. Return of the psychedelics: Psilocybin for treatment resistant depression. Asian journal of psychiatry. vol 24. 2017-02-14. PMID:27931907. |
the efficacy of psilocybin in clinical depression previously demonstrated in the elecrophysiologic and neuroimaging findings as also in neuropsychological assessments is further validated by the findings of this rigorously conducted randomized trial. |
2017-02-14 |
2023-08-13 |
Not clear |